ImmuneRegen BioSciences Appoints Dr. Martina Cartwright to Bioterrorism Preparedness Advisory Board

Top Critical Care Specialist Joins Board as Advisor

Apr 01, 2005, 00:00 ET from ImmuneRegen BioSciences

    SCOTTSDALE, Ariz., April 1 /PRNewswire-FirstCall/ -- Research and
 development biotechnology company ImmuneRegen BioSciences, a wholly owned
 subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board:   IRBO), has
 named top research scientist Martina M. Cartwright, Ph.D., R.D., as Associate
 Advisor to its newly established Bioterrorism Preparedness Advisory Board.
 The U.S. Food and Drug Administration (FDA) and the Department of Counter
 Terrorism (DCT) has requested that ImmuneRegen form the board to develop an
 emergency deployment plan for ImmuneRegen's proprietary compound, Radilex(TM).
 Having undergone its seventh stage of testing, Radilex is a treatment
 currently in development to counteract the effects of lethal radiation
 dosages, anthrax or ricin poisoning, as well as similar inhalants.
     Dr. Cartwright will be charged, along with her fellow board members, with
 developing a plan to disseminate the proprietary and potentially life-saving
 Radilex in the event of a biological or nuclear disaster.  The ImmuneRegen
 Bioterrorism Preparedness Advisory Board will also be available to support
 local, federal, and international officials in dealing with the possible
 threat of another terrorist attack.
     "As concerned Americans, we all need to be taking the potential threats of
 a bioterror-related attack a lot more seriously," remarked Dr. Cartwright.
 "It's very gratifying to be able to contribute to such a focused and
 worthwhile organization as ImmuneRegen's Advisory Board."
     Dr. Cartwright will be instrumental in assisting Dr. Mark Witten, Advisory
 Board Chairman and ImmuneRegen BioSciences Co-Founder.  Other members of the
 Bioterrorism Preparedness Advisory Board include Dr. William E. Hoehn, a
 veteran of legislative and executive branches of the federal government and a
 researcher and executive at a major think tank, as well as Michael Caridi,
 security industry entrepreneur and real estate developer.
     "Dr. Cartwright's in-depth background in the fields of Trauma and Critical
 Care are of incalculable importance to our Bioterrorism Preparedness Advisory
 Board," said Michael Wilhelm, ImmuneRegen's CEO.  "Her knowledge and
 experience will benefit us greatly, especially in helping to guide our
 clinical research protocols related to bioterrorism and other applications."
     More About Dr. Cartwright
     Dr. Cartwright is a highly respected research scientist, specializing in
 the areas of Trauma, Critical Care, Nutrition, and Oncology.  She currently
 works out of the University of Arizona as a private consultant on bioterrorism
 preparedness.  She serves on the Board of Directors of the University of
 Arizona College of Agriculture and Life Sciences and also as a Curriculum
 Advisor to San Diego State University/US Naval Hospital and as an Adjunct
 Faculty member at University of Arizona Department of Nutritional Sciences.
 Her professional memberships include American Dietetic Association/Sports,
 Cardiovascular Practice Group, Society of Nutrition Education, and Nevada
 Dietetic Association.
     About ImmuneRegen BioSciences, Inc.
     ImmuneRegen BioSciences, Inc. is a biotechnology company engaged in the
 research and development of applications utilizing modified substance P, a
 naturally occurring immunomodulator.  The company's product, Homspera(TM), is
 derived from homeostatic substance P.   The ongoing focus of ImmuneRegen
 BioSciences has been the continuing development of Homspera for various
 applications including the improvement of pulmonary function and the
 stimulation of the human immune system.  The Homspera compound is also being
 developed as a therapeutic treatment in several other applications including
 radiation sickness (Radilex(TM)) and viral infection/biological warfare
 scenarios (Viprovex(TM)).  For more information, please visit the company's
 website at
     About Radilex(TM)
     Radilex is a treatment currently in development for the negative effects
 of radiation, anthrax, ricin poisoning and other poisonous inhalants.  Testing
 has shown a significant survival rate of radiation exposure at a 7.75 gray
 level, which is a lethal dosage.  Radilex was derived from discoveries made
 during research funded by the Air Force Office of Scientific Research in the
 early 1990s.  During this research, Dr. Mark Witten and his associates
 observed that exposure to jet fuels resulted in pathological changes in the
 lungs and immune systems of those exposed.  It was also observed that such
 exposure resulted in depletion of substance P from the lungs.  These studies
 further showed that the administration of substance P might help prevent and
 reverse the effects of jet fuel exposure in the lungs, as well as protect and
 regenerate the immune system.
     Statements about the Company's future expectations, including future
 revenues and earnings, and all other statements in this press release other
 than historical facts, are "forward-looking statements" within the meaning of
 Section 27A of the Securities Act of 1933, Section 21E of the Securities
 Exchange Act of 1934, and as that term is defined in the Private Securities
 Litigation Reform Act of 1995.  The Company intends that such forward-looking
 statements be subject to the safe harbors created thereby.  The Company's
 actual results could differ materially from expected results as a result of a
 number of factors, including the uncertainties inherent in research
 collaborations, clinical trials and product development programs, the
 evaluation of potential opportunities, the level of corporate expenditures,
 capital market conditions, and others.
      Contact: W. Jason Grimley
               Spelling Communications

SOURCE ImmuneRegen BioSciences